Mutual of America Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $367K | Buy |
14,513
+186
| +1% | +$4.09K | ﹤0.01% | 1226 |
|
|
2026
Q1 | $319K | Buy |
14,327
+18
| +0.1% | +$430 | ﹤0.01% | 1190 |
|
|
2025
Q4 | $382K | Buy |
14,309
+324
| +2% | +$7.74K | ﹤0.01% | 1130 |
|
|
2025
Q3 | $298K | Sell |
13,985
-1,925
| -12% | -$45.5K | ﹤0.01% | 1189 |
|
|
2025
Q2 | $343K | Sell |
15,910
-2,020
| -11% | -$37.5K | ﹤0.01% | 1170 |
|
|
2025
Q1 | $298K | Buy |
+17,930
| New | +$326K | ﹤0.01% | 1236 |
|
|
2024
Q2 | – | Sell |
-66,930
| Closed | -$1.24M | – | 1453 |
|
|
2024
Q1 | $1.24M | Sell |
66,930
-3,540
| -5% | -$87.7K | 0.01% | 1013 |
|
|
2023
Q4 | $2.21M | Buy |
+70,470
| New | +$1.68M | 0.03% | 859 |
|
|
2022
Q2 | – | Sell |
-100,238
| Closed | -$2.43M | – | 1627 |
|
|
2022
Q1 | $2.43M | Sell |
100,238
-4,360
| -4% | -$106K | 0.03% | 877 |
|
|
2021
Q4 | $2.44M | Sell |
104,598
-977
| -0.9% | -$19.6K | 0.02% | 903 |
|
|
2021
Q3 | $1.75M | Sell |
105,575
-5,231
| -5% | -$101K | 0.02% | 985 |
|
|
2021
Q2 | $2.7M | Buy |
110,806
+50,854
| +85% | +$1.15M | 0.03% | 852 |
|
|
2021
Q1 | $1.55M | Sell |
59,952
-498
| -0.8% | -$21.9K | 0.02% | 1031 |
|
|
2020
Q4 | $3.23M | Sell |
60,450
-1,412
| -2% | -$70.1K | 0.04% | 703 |
|
|
2020
Q3 | $2.55M | Sell |
61,862
-9,844
| -14% | -$425K | 0.03% | 703 |
|
|
2020
Q2 | $3.48M | Sell |
71,706
-31,370
| -30% | -$1.51M | 0.05% | 539 |
|
|
2020
Q1 | $4.36M | Sell |
103,076
-4,534
| -4% | -$187K | 0.07% | 333 |
|
|
2019
Q4 | $4.6M | Sell |
107,610
-746
| -0.7% | -$32.5K | 0.06% | 473 |
|
|
2019
Q3 | $3.9M | Sell |
108,356
-603
| -0.6% | -$18.3K | 0.05% | 530 |
|
|
2019
Q2 | $2.91M | Buy |
108,959
+71
| +0.1% | +$1.81K | 0.04% | 701 |
|
|
2019
Q1 | $2.92M | Buy |
108,888
+1,973
| +2% | +$46.1K | 0.04% | 674 |
|
|
2018
Q4 | $1.73M | Sell |
106,915
-53,300
| -33% | -$1.03M | 0.03% | 867 |
|
|
2018
Q3 | $3.33M | Sell |
160,215
-4,736
| -3% | -$74.5K | 0.05% | 636 |
|
|
2018
Q2 | $2.52M | Buy |
164,951
+55,687
| +51% | +$993K | 0.04% | 773 |
|
|
2018
Q1 | $2.46M | Buy |
109,264
+61,700
| +130% | +$1.71M | 0.04% | 761 |
|
|
2017
Q4 | $1.43M | Sell |
47,564
-87
| -0.2% | -$2.78K | 0.02% | 1001 |
|
|
2017
Q3 | $1.79M | Sell |
47,651
-27,415
| -37% | -$892K | 0.03% | 881 |
|
|
2017
Q2 | $2.09M | Sell |
75,066
-2,541
| -3% | -$75.7K | 0.04% | 808 |
|
|
2017
Q1 | $2.67M | Sell |
77,607
-1,404
| -2% | -$49.6K | 0.05% | 673 |
|
|
2016
Q4 | $2.28M | Buy |
79,011
+1,554
| +2% | +$41.1K | 0.04% | 715 |
|
|
2016
Q3 | $2.46M | Hold |
77,457
| – | – | 0.05% | 628 |
|
|
2016
Q2 | $2.51M | Hold |
77,457
| – | – | 0.05% | 586 |
|
|
2016
Q1 | $2.17M | Sell |
77,457
-500
| -0.6% | -$10.9K | 0.05% | 631 |
|
|
2015
Q4 | $2.78M | Buy |
77,957
+466
| +0.6% | +$16.4K | 0.06% | 493 |
|
|
2015
Q3 | $2.56M | Hold |
77,491
| – | – | 0.06% | 512 |
|
|
2015
Q2 | $3.25M | Hold |
77,491
| – | – | 0.07% | 418 |
|
|
2015
Q1 | $2.52M | Buy |
77,491
+37,776
| +95% | +$1.3M | 0.05% | 593 |
|
|
2014
Q4 | $1.26M | Buy |
+39,715
| New | +$1.13M | 0.03% | 908 |
|
Other funds holding ACAD
N
PAM
Mutual of America Capital Management's ACAD Position: Q2 2026 in Review
Mutual of America Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 1.3% in Q2 2026, buying an estimated $4.09K and bringing the position to 14,513 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #1226.
Mutual of America Capital Management first reported a position in ACAD in Q4 2014 and has held it in 38 quarters since. The position peaked at $4.6M in Q4 2019. 168 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Mutual of America Capital Management held 14,513 shares of Acadia Pharmaceuticals worth $367K as of Q2 2026.
- Mutual of America Capital Management bought 186 Acadia Pharmaceuticals shares in Q2 2026, an estimated $4.09K.
- Acadia Pharmaceuticals made up ﹤0.01% of Mutual of America Capital Management's portfolio in Q2 2026, its #1226 holding.
- Mutual of America Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 38 quarters since.
- Mutual of America Capital Management's Acadia Pharmaceuticals position peaked at $4.6M in Q4 2019.
- 168 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.